Schering-Plough’s new trial model
This article was originally published in The Tan Sheet
Executive Summary
A new global model for clinical trial operations will be adopted by Schering-Plough to improve the planning and management of the progression of therapeutic compounds during the clinical trial process. The Global Clinical Harmonization program is "designed to maximize its product portfolio through centralized global processes and function units that are efficient, compliant and customer-focused," the company states in a release June 6. The Global Clinical Operations will establish a "global set of standards, policies and practices, and build a management system that will oversee clinical trials worldwide," the firm explains. All trials will be held to these standards regardless of trial type, phase or geography. The adoption of the new model marks another step in Schering-Plough's Action Agenda to build the firm into a "high-performance competitor for the long term," according to Chairman and CEO Fred Hassan. The firm recently began a consolidation of its operating facilities which will affect approximately 1,100 positions and close the Manati, Puerto Rico manufacturing site (1"The Tan Sheet" June 5, 2006, In Brief)...
You may also be interested in...
Schering-Plough consolidates operations
Schering-Plough will begin "phasing out" manufacturing operations at its Manati, Puerto Rico site, with complete closure anticipated by the end of the year, the pharmaceutical firm announces June 1. The company also anticipates workforce reductions at its facilities located in Las Piedras, Puerto Rico and New Jersey. The facilities consolidation will affect a total of approximately 1,100 positions, mostly in 2006, and is part of an effort to "streamline its global supply chain and further enhance the company's long-term competitiveness," the firm states. Schering-Plough expects $235 mil. to $260 mil. in charges associated with severance pay, fixed asset and inventory write-offs, and accelerated depreciation and closure costs, about half of which will be incurred in the second quarter of 2006. "The remaining expenses are expected to be recorded in the second half of 2006 as incurred," the firm says. Products affected by the closing of the Manati facility include Afrin (oxymetazoline HCl) nasal spray. Manufacturing operations for the topical sinus spray will be relocated to the Cleveland, Tenn. facility, according to Schering-Plough...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.